

Funding sources

Lung Cancer Europe

2018

LuCE industry related income		
Name of company/funder	Amount of income	% of overall organisations income
ABBVIE	9.239,50 CHF	3,40%
AMGEN	29.554,25 CHF	10,88%
ARES TRADING	14.535,05 CHF	5,35%
ASTRAZENECA	22.811,60 CHF	8,40%
BOEHRINGER INGELHEIM	23.510,20 CHF	8,65%
BRISTOL-MYERS	29.138,50 CHF	10,73%
HOFFMANN-LA ROCHE	64.151,00 CHF	23,61%
MSD INTERNATIONAL	23.109,00 CHF	8,51%
NOVARTIS	22.841,20 CHF	8,41%
TAKEDA	23.450,40 CHF	8,63%
OTHER REFUNDS INDUSTRY	6.158,40 CHF	2,27%
Subtotal	268.499,10 CHF	98,83%

LuCE non-industry related income – Public funding		
Name of company/funder	Amount of income	% of overall organisations income
None	-	0,00%
Subtotal	-	0,00%

LuCE non-industry related income		
Name of company/funder	Amount of income	% of overall organisations income
Members contribution	1.410,10 CHF	0,52%
ESO – European School of Oncology	1.502,90 CHF	0,55%
Other refunds non-industry	269,56 CHF	0,10%
Subtotal	3.182,56 CHF	1,17%

TOTAL	271.681,66 CHF	100,00%
--------------	-----------------------	----------------

Summary

Overall proportion of industry and non-industry

Industry: 98.83%; Non-Industry: 1.17%

Percentage of the highest contribution from a single company

23.61 % of overall organizations income